BIV 201

Drug Profile

BIV 201

Alternative Names: BIV201

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator BioVie
  • Class Vasoconstrictors
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ascites
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ascites

Most Recent Events

  • 29 Nov 2016 BioVie submits an IND application with the US FDA in USA for Ascites
  • 09 Sep 2016 Preclinical trials in Ascites in USA (unspecified route) before September 2016
  • 09 Sep 2016 BioVie announces intention to submit IND to US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top